Gotham Asset Management’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-3,545
Closed -$309K 1559
2024
Q4
$309K Buy
+3,545
New +$325K ﹤0.01% 1254
2022
Q3
Sell
-5,694
Closed -$288K 1179
2022
Q2
$288K Buy
+5,694
New +$334K 0.01% 952
2021
Q3
Sell
-15,324
Closed -$1.35M 1029
2021
Q2
$1.35M Buy
15,324
+7,794
+104% +$714K 0.06% 412
2021
Q1
$732K Buy
7,530
+3,719
+98% +$371K 0.03% 575
2020
Q4
$427K Buy
+3,811
New +$402K 0.01% 743
2019
Q3
Sell
-2,631
Closed -$248K 1095
2019
Q2
$248K Buy
+2,631
New +$217K ﹤0.01% 1003
2017
Q2
Sell
-25,305
Closed -$1.01M 972
2017
Q1
$1.01M Buy
+25,305
New +$906K 0.01% 665
2016
Q4
Sell
-8,656
Closed -$257K 950
2016
Q3
$257K Buy
+8,656
New +$215K ﹤0.01% 814

Other funds holding BPMC

Gotham Asset Management's BPMC Position: Q1 2025 in Review

Gotham Asset Management sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 3,545 shares — an estimated $309K sold.

Gotham Asset Management first reported a position in BPMC in Q3 2016 and held it in 8 quarters. The position peaked at $1.35M in Q2 2021. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Gotham Asset Management reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Gotham Asset Management sold 3,545 Blueprint Medicines shares in Q1 2025, an estimated $309K.
  • Gotham Asset Management first reported a position in Blueprint Medicines in Q3 2016 and held it in 8 quarters.
  • Gotham Asset Management's Blueprint Medicines position peaked at $1.35M in Q2 2021.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Gotham Asset Management's 13F filing for Q1 2025, filed 15 May 2025.